MyNovocure®

Around-the-clock support, when and where you need it

the support program that is always within reach

Anytime, Anywhere: The support your patients can count on

Whether they are at home, at work, or even on a mountain trail, MyNovocure provides a unique support system that patients can rely on at every stage of their treatment.

What is MyNovocure?

MyNovocure is an all-encompassing support program created to provide patients and their families with direct, personalized assistance. Through a combination of device support specialists (DSSs), 24/7 resources, and easy access to educational and troubleshooting materials, MyNovocure empowers patients to integrate Optune Gio into their daily routines.

Key components of MyNovocure

Travel support

Insurance support

Tips for integrating Optune Gio into daily life

24/7 technical support and troubleshooting

Device training as needed (how Optune Gio works, side effects, etc)

Reordering supplies (eg, arrays + batteries)

Taylor smiling with his arms crossed, wearing the Optune Gio arrays and backpack.

Taylor is an Optune Gio user and Patient Ambassador. Patient images reflect the health status of the patient at the time each photo was taken.

The MyNovocure program is more than a support system—it is a partner in your treatment journey, helping patients live confidently and comfortably with Optune Gio, no matter where life takes them.

Personalized on-demand support

For many patients, navigating a new treatment can be daunting. MyNovocure offers the peace of mind that comes with always having an expert just a call away. Each Device Support Specialist (DSS) is trained not only in the technical aspects of Optune Gio but also in providing compassionate, patient-centered support. This means that patients can feel comfortable reaching out, knowing their questions will be met with understanding and expertise.

Flexibility to match patients’ lives

The MyNovocure program isn’t confined to a clinic or limited to office hours—it is an “anytime, anywhere” resource, designed to fit seamlessly into patients’ lives. This makes Optune Gio a manageable part of their treatment plan, helping them integrate it into their daily routines with minimal disruption.

Empowerment through education and support

By combining real-time support with a full library of resources, MyNovocure gives patients and caregivers the knowledge they need to use Optune Gio effectively. Patients are empowered to become active participants in their own care, equipped with the information and confidence needed to embrace Optune Gio.

MyNovocure provides 24/7 assistance for your practice and patients throughout the treatment journey

 

Contact us any time of day

Call us 24/7

1-855-281-9301

MyNovocure cannot provide any medical advice. To ensure proper guidance, MyNovocure will direct your patients to ask any treatment-related questions to you.

Partnering with your patients and practice at every step of the journey

Erica assisting Steve with a laptop, highlighting supportive care and guidance.

Steve is a patient. Erica is his MyNovocure Device Support Specialist (DSS). Patient image reflects the health status of patient at the time photo was taken.

From prescription to ongoing treatment, Novocure offers patients a seamless journey of support. Starting with easy certification and submission, the Novocure team guides each patient through benefits investigation and personalized onboarding. Once treatment begins, Device Support Specialists provide live training and 24/7 assistance, with monthly check-ins and resources to help integrate Optune Gio into daily life. With MyNovocure®, patients receive the guidance they need to confidently navigate each step of their journey.

For Your Practice

 

Step 1: Get certified

  • Reach out to a Territory Manager to complete an in-person or online certification

 

Step 2: Submit the prescription form

  • Complete and submit all pages of the prescription form with the necessary documentation listed below via fax, email, or paper form. Patient MRI for the array map should be submitted at this time. 
    • Copy of patient insurance card
    • Medical records (history and physical)
    • Clinical notes
    • Patient’s most recent MRI scans with and without contrast

 

 

For Novocure's Team

 

Step 3: Reimbursement assistance

  • Benefits Investigation begins to assess optimal coverage, followed by insurance authorization

 

Step 4: Welcome call

  • The patient receives a welcome call within 72 hours of Rx approval from a Financial Coordinator. The Financial Coordinator will review financial responsibility with the patient based on benefits investigation and will work with the MyNovocure® team to schedule a start appointment and notify the practice 

 

Step 5: Treatment planning

  • The array layout and map will be shared with your practice prior to the patient’s start appointment
Man wearing Optune Gio points playfully at a woman as they both relax in a living room.

Actor portrayal.

Patient's start and beyond

 

Step 6: Patient start appointment

  • A Device Support Specialist (DSS) delivers Optune Gio to the patient’s home or your practice and provides live training and continued support. DSS will inform your practice once the patient start is scheduled 
  • A DSS will contact your practice if there are any changes to the patient start
  • Once a patient begins, their HCP can track their progress through MyLinkTM 

 

Step 7: Ongoing support

  • Once a patient begins treatment, MyNovocure will offer continued support by: 
  • Providing 24/7 support via phone or email. SMS available during normal business hours only
  • Checking in on the patient monthly to discuss usage and any supply reorders
  • Offering tips and resources related to daily life with Optune Gio, when necessary

MRI, magnetic resonance imaging; SMS, short message service.

Indications For Use

Optune Gio® is intended as a treatment for adult patients (22 years of age or older) with histologically confirmed glioblastoma multiforme (GBM).

 

Optune Gio with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

 

For the treatment of recurrent GBM, Optune Gio is indicated following histologically or radiologically confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
 

Important Safety Information

Contraindications

Do not use Optune Gio in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune Gio together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune Gio together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune Gio ineffective.

 

Do not use Optune Gio in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Gio may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

 

Warnings and precautions

Optune Gio can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

 

Do not prescribe Optune Gio for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune Gio in these populations have not been established.

 

The most common (≥10%) adverse events involving Optune Gio in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

 

The most common (≥10%) adverse events seen with Optune Gio monotherapy were medical device site reaction and headache.
The following adverse reactions were considered related to Optune Gio when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer.

 

Use of Optune Gio in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune Gio in these patients could lead to tissue damage or lower the chance of Optune Gio being effective.

 

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune Gio treatment.

Please click here to see the Optune Gio® Instructions For Use for complete information regarding the device’s indications, contraindications, warnings, and precautions.

 

References

1. Optune Gio. Instructions For Use. Novocure; 2023. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495-504. doi:10.1001/jamaoncol.2017.5082 3. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. doi:10.1001/ jama.2017.18718 4. Novocure Data on File US-DOF-0035. 5. Novocure Data on File US-DOF-0038. 6. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330 8. Sulman EP, Ismaila N, Armstrong TS, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2017;35(3):361-369. doi:10.1200/JCO.2016.70.7562 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 27, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 10. Kinzel A, Ambrogi M, Varshaver M, Kirson ED. Tumor treating fields for glioblastoma treatment: patient satisfaction and compliance with the second-generation Optune® system. Clin Med Insights Oncol. 2019:13: 1179554918825449. doi:10.1177/1179554918825449 11. Novocure Data on File US-DOF-0049. 12. Optune. Patient Information and Operation Manual for Glioblastoma Multiforme. Novocure; 2023. 13. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984 14. Ahmad MA, Al Natour Z, Mustafa F, Rizvi TA. Electrical characterization of normal and cancer cells. IEEE Access. 2018;6:25979-25986. doi:10.1109/ACCESS.2018.2830883 15. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-3295. doi:10.1158/0008-5472.can-04-0083 16. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10(5):e0125269. doi:10.1371/journal.pone.0125269 17. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046. doi:10.1038/srep18046 18. Novocure Data on File US-DOF-0052. 19. Vanderbeek AM, Rahman R, Fell G, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018;20(8):1034-1043. doi:10.1093/neuonc/noy027 20. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. Supplement 1. Trial protocol and statistical analysis plan. JAMA. 2017;318(23):2306-2316. Accessed January 9, 2025. https://jamanetwork.com/journals/jama/fullarticle/2666504 21. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2019;141(2):467-473. doi:10.1007/s11060-018-03057-z 22. Ram Z, Kim CY, Hottinger AF, Idbaih A, Nicholas G, Zhu JJ. Efficacy and safety of Tumor Treating Fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial. Front Oncol. 2021;11:671972. doi:10.3389/fonc.2021.671972 23. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields and health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. Supplementary online content. JAMA Oncol. 2018;4(4):495-504. Accessed January 9, 2025. https://jamanetwork.com/journals/jamaoncology/fullarticle/2670704 24. EORTC Quality of Life Group. EORTC QLQ-C30, Version 3.0. 1995. European Organisation for Research and Treatment of Cancer, Belgium. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf 25. Zhu JJ, Demireva P, Kanner AA, et al. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2017;135(3):545-552. doi:10.1007/s11060-017-2601-y 26. Novocure Data on File OPT-103. 27. Lacouture ME, Anadkat MJ, Ballo MT, et al. Prevention and management of dermatologic adverse events associated with Tumor Treating Fields in patients with glioblastoma. Front Oncol. 2020;10:1045. doi:10.3389/fonc.2020.01045 28. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202. doi:10.1016/j.ejca.2012.04.011 29. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Supplementary Table 1. Eur J Cancer. 2012;48(14):2192-2202. Accessed January 10, 2025. https://www.ejcancer.com/article/S0959-8049(12)00352-8/fulltext 30. Wong ET, Lok E, Swanson KD, et al. Response assessment of NovoTTF-100A versus best physician’s choice chemotherapy in recurrent glioblastoma. Cancer Med. 2014;3(3):592-602. doi:10.1002/cam4.210 31. Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice of chemotherapy. Semin Oncol. 2014;41(suppl 6):S25-S34. doi:10.1053/j. seminoncol.2014.09.008 32. Novocure Data on File OPT-109. 33. Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. J Neurooncol. 2023;164(1):1-9. doi:10.1007/s11060-023-04348-w 34. Bähr O, Tabatabai G, Fietkau R, Goldbrunner R, Glas M. Tumor Treating Fields therapy in patients with newly diagnosed glioblastoma: long-term survival results from TTFields in Germany in Routine Clinical Care (TIGER) study. Poster presented at: American Society of Clinical Oncology; May 31–June 4, 2024; Chicago, IL. 35. Palmer JD, Chavez G, Furnback W, et al. Health-related quality of life for patients receiving tumor treating fields for glioblastoma. Front Oncol. 2021;11:772261. doi:10.3389/fonc.2021.772261

Novocure Websites

This website is intended for people seeking information on Optune Gio.

 

On this site, videos and images identified as Optune Gio users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals.

 

Patient images reflect the health status of the patients at the time each photo or video was taken.

 

External links

Optunegio.com
Optunelua.com

Quick links

What is Optune Gio?
Mechanism of Action
International
Contact Us

Legal links

Terms of Use
Privacy Notice
Novocure logo

©2025 Novocure GmbH. All Rights Reserved. 

MyLink, MyNovocure, Novocure, and Optune Gio are registered trademarks of Novocure GmbH.

All other trademarks, registered or unregistered, are the property of their respective owners. 

US-OPG-00982 v1.0 July 2025

US-OPG-00982 v1.0 July 2025